, Tracking Stock Market Picks
Enter Symbol:
Aeterna Zentaris, Inc. (AEZS) [hlAlert]

down 98.82 %

Aeterna Zentaris, Inc. (AEZS) rated Buy with price target $2.65 by Canaccord Adams

Posted on: Tuesday,  Jun 3, 2008  11:25 AM ET by Canaccord Adams

Canaccord Adams rated Buy Aeterna Zentaris, Inc. (NASDAQ: AEZS) on 06/03/2008. Previously Canaccord Adams rated Buy Aeterna Zentaris, Inc. (NASDAQ: AEZS) on
04/14/2008., when the stock price was $7.68. Since then, Aeterna Zentaris, Inc. has lost 98.83% as of 12/02/2015's recent price of $0.09.
If you would have followed the previous Canaccord Adams's recommendation on AEZS, you would have lost 98.82% of your investment in 2788 days.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology. The product pipeline of the Company encompasses compounds at all stages of development, from drug discovery through marketed products. The Company’s principal product candidates include cetrorelix for benign prostatic hyperplasia (BPH) and AEZS-108 for endometrial and ovarian cancers. In January 2007, the Company completed the spin-off of Atrium Biotechnologies Inc., known as Atrium Innovations (Atrium). On November 30, 2007, the Company completed the sale of its Utah-based subsidiary, Echelon Biosciences Inc. (Echelon), to Frontier Scientific Inc.

Canaccord Adams provides focused, actionable, idea-driven research, helping clients make informed investment decisions. Our 55 international analysts scour the globe for emerging and small to mid cap (US$1-2 billion market capitalization) growth opportunities, identifying value and exposing risk. Our research team analyzes over 550 companies in eight sectors, clarifying current events and anticipating market trends in high-quality daily, weekly and monthly research products. Our clients benefit from our thorough and sophisticated knowledge of the sectors we cover - Metals and Mining, Energy, Technology, Life Sciences, Real Estate, Consumer, Sustainability and Industrial Growth. We combine independent, actionable ideas, unique global perspective and unparalleled industry expertise. We believe it's evident in our research, and the foundation of our business.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/3/2008 11:25 AM Buy
8.82 15.90
as of 12/24/2008
1 Week down  -10.93 %
1 Month up  35.71 %
3 Months up  75.38 %
1 YTD up  132.65 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/14/2008 11:25 AM Buy
7.68 19.20

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy